Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of intravesical FL115 alone or with BCG in non-muscle-invasive bladder cancer
CTR20242361Phase 2Active
- Sponsor
- Suzhou Furong Biotechnology
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FL-115 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Suzhou Furong Biotechnology. Started Aug 2024; status: active.
02
Drugs
FL-115
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20242361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242361.